The Role of Pro-angiogenic Immune Cells in Human Pregnancies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Hillel Yaffe Medical Center.
Recruitment status was  Recruiting
Information provided by:
Hillel Yaffe Medical Center Identifier:
First received: May 12, 2010
Last updated: August 5, 2010
Last verified: August 2010
Identification of the presence of proangiogenic immune cells in normal human placentas may enable predication of some pregnancy disorders.

Condition Intervention
Fetal Growth Retardation
Other: Biological specimen

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • To find the angiogenic potential of proangiogenic immune cells derived from human placentas. [ Time Frame: Two years ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: August 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Placentas after delivery or abortion Other: Biological specimen
Biological specimen taken from placenta


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Placentas after delivery or abortion

Inclusion Criteria:

  • Placentas that have been delivered in the Medical Center

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01177020

Contact: Elad Mei-Dan, MD 972-4-6304248

Hillel Yaffe Medical Center Recruiting
Hadera, Israel, 38100
Principal Investigator: Elad Meidan, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Elad Mei-Dan, MD, Hillel Yaffe Medical Center Identifier: NCT01177020     History of Changes
Other Study ID Numbers: HYMC1069A 
Study First Received: May 12, 2010
Last Updated: August 5, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Fetal Growth Retardation
Fetal Diseases
Growth Disorders
Pathologic Processes
Pregnancy Complications processed this record on May 24, 2016